Andy Cooper

In this discussion, Andy Cooper, CEO of CluePoints and a veteran in clinical data analytics, tackles the misconceptions surrounding AI in clinical trials. He explains the essential differences between supervised and unsupervised machine learning, emphasizing the need for domain-specific models. Andy highlights the potential of AI to predict site issues and streamline operations by reducing manual tasks. He also addresses concerns about data privacy and trust in AI tools, advocating for consistent results over transparency to build confidence in machine learning.